

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

**VOLUNTARY ANNOUNCEMENT**  
**SHARE PURCHASE PURSUANT TO THE 2022 H SHARE**  
**INCENTIVE SCHEME**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (上海百心安生物技術股份有限公司) (the “**Company**”) on a voluntary basis. Reference is made to the announcement of the Company dated May 11, 2022 (the “**Announcement**”), and the circular dated May 20, 2022 (the “**Circular**”), in relation to the adoption of the 2022 H Share Incentive Scheme. Capitalized terms used herein shall have the same meanings as those defined in the Announcement and Circular unless the context requires otherwise.

On August 24, 2022, the Trustee purchased a total number of 24,100 H Shares on the market, at a consideration from approximately HK\$56.05 to HK\$56.35 per Share and a total consideration of approximately HK\$1,353,550.00 in aggregate, representing approximately 0.0391% of the shareholding in H Class of shares and approximately 0.0099% of the total issued share capital of the Company, pursuant to the 2022 H Share Incentive Scheme as a long-term equity incentive for employees in the future. The total number of H shares held by the Trustee immediately after the purchase is 396,400 Shares.

As at the date of this announcement, no RSUs have been granted to any Selected Persons to the 2022 H Share Incentive Scheme. The Board of Directors or its Delegatee will have full discretion to determine the number of shares to be granted to Selected Persons under the 2022 H Share Incentive Scheme together with vesting criteria and conditions as it deems appropriate.

The Company may make further announcements on the status of the 2022 H Share Incentive Scheme, including the number and price of the Shares purchased, from time to time.

By order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and Executive Director*

Shanghai, the People's Republic of China, August 24, 2022

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive Director, Mr. Yunqing WANG as executive Director, Ms. Li CAI, Mr. Quan ZHOU, and Mr. Ji CHEN as non-executive Directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive Directors.*